Proteomics of ovarian cancer: functional insights and clinical applications

Cancer and Metastasis Reviews

Volumn 34, Issue 1, 2015, Pages 83-96

  Elzek, Mohamed A ^a,b   Rodland, Karin D ^b  

^a Egybiotech for Research and Biotechnology   (Egypt)

^b PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

Author keywords

Biomarker; Drug resistance; Ovarian cancer; Proteomics; Subtypes

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEOME; TUMOR MARKER;

ANTAGONISTS AND INHIBITORS; FEMALE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; OVARIAN NEOPLASMS; PROCEDURES; PROTEOMICS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84925446721     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-014-9547-8     Document Type: Article

References (143)

1. Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014). Cancer statistics, 2014. CA: A Cancer Journal for Clinicians, 64(1), 9–29. doi:10.3322/caac.21208.
2. Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T., Troyanskaya, O., Diehn, M., et al. (2003). Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell, 14(11), 4376–4386. doi:10.1091/mbc.E03-05-0279.
3. Kobel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., et al. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medicine, 5(12), e232. doi:10.1371/journal.pmed.0050232.
4. Singer, G., Kurman, R. J., Chang, H. W., Cho, S. K., & Shih Ie, M. (2002). Diverse tumorigenic pathways in ovarian serous carcinoma. American Journal of Pathology, 160(4), 1223–1228.
5. Kurman, R. J., & Shih Ie, M. (2011). Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. Human Pathology, 42(7), 918–931. doi:10.1016/j.humpath.2011.03.003.
6. Integrated genomic analyses of ovarian carcinoma (2011). Nature, 474(7353), 609–615. doi:10.1038/nature10166.
7. Landen, C. N., Jr., Birrer, M. J., & Sood, A. K. (2008). Early events in the pathogenesis of epithelial ovarian cancer. Journal of Clinical Oncology, 26(6), 995–1005. doi:10.1200/jco.2006.07.9970.
8. Dubeau, L. (1999). The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecologic Oncology, 72(3), 437–442. doi:10.1006/gyno.1998.5275.
9. Dubeau, L. (2008). The cell of origin of ovarian epithelial tumours. Lancet Oncology, 9(12), 1191–1197. doi:10.1016/s1470-2045(08)70308-5.
10. Kurman, R. J., & Shih Ie, M. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. American Journal of Surgical Pathology, 34(3), 433–443. doi:10.1097/PAS.0b013e3181cf3d79.
11. Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., et al. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. American Journal of Surgical Pathology, 31(2), 161–169. doi:10.1097/01.pas.0000213335.40358.47.
12. Crum, C. P., Drapkin, R., Kindelberger, D., Medeiros, F., Miron, A., & Lee, Y. (2007). Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clinical Medicine & Research, 5(1), 35–44. doi:10.3121/cmr.2007.702.
13. Nik, N. N., Vang, R., Shih Ie, M., & Kurman, R. J. (2014). Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annual Review of Pathology, 9, 27–45. doi:10.1146/annurev-pathol-020712-163949.
14. Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., et al. (2011). Global quantification of mammalian gene expression control. Nature, 473(7347), 337–342. doi:10.1038/nature10098.
15. Wu, L., Candille, S. I., Choi, Y., Xie, D., Jiang, L., Li-Pook-Than, J., et al. (2013). Variation and genetic control of protein abundance in humans. Nature, 499(7456), 79–82. doi:10.1038/nature12223.
16. Ellis, M. J., Gillette, M., Carr, S. A., Paulovich, A. G., Smith, R. D., Rodland, K. K., et al. (2013). Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. Cancer Discovery, 3(10), 1108–1112. doi:10.1158/2159-8290.cd-13-0219.
17. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., et al. (2014). Proteogenomic characterization of human colon and rectal cancer. Nature, 513(7518), 382–387. doi:10.1038/nature13438.
18. Chevalier, F. (2010). Highlights on the capacities of “gel-based” proteomics. Proteome Science, 8, 23. doi:10.1186/1477-5956-8-23.
19. Spurrier, B., Ramalingam, S., & Nishizuka, S. (2008). Reverse-phase protein lysate microarrays for cell signaling analysis. Nature Protocols, 3(11), 1796–1808. doi:10.1038/nprot.2008.179.
20. Aebersold, R., & Mann, M. (2003). Mass spectrometry-based proteomics. Nature, 422(6928), 198–207. doi:10.1038/nature01511.
21. Yates, J. R., Ruse, C. I., & Nakorchevsky, A. (2009). Proteomics by mass spectrometry: approaches, advances, and applications. Annual Review of Biomedical Engineering, 11, 49–79. doi:10.1146/annurev-bioeng-061008-124934.
22. Bantscheff, M., Lemeer, S., Savitski, M. M., & Kuster, B. (2012). Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Analytical and Bioanalytical Chemistry, 404(4), 939–965. doi:10.1007/s00216-012-6203-4.
23. Gustafsson, O. J., Arentz, G., & Hoffmann, P. (2014). Proteomic developments in the analysis of formalin-fixed tissue. Biochimica et Biophysica Acta. doi:10.1016/j.bbapap.2014.10.003.
24. Lawrie, L. C., Curran, S., McLeod, H. L., Fothergill, J. E., & Murray, G. I. (2001). Application of laser capture microdissection and proteomics in colon cancer. Molecular Pathology, 54(4), 253–258.
25. Espina, V., Wulfkuhle, J. D., Calvert, V. S., VanMeter, A., Zhou, W., Coukos, G., et al. (2006). Laser-capture microdissection. Nature Protocols, 1(2), 586–603. doi:10.1038/nprot.2006.85.
26. Fowler, C. B., O’Leary, T. J., & Mason, J. T. (2013). Toward improving the proteomic analysis of formalin-fixed, paraffin-embedded tissue. Expert Review of Proteomics, 10(4), 389–400. doi:10.1586/14789450.2013.820531.
27. Konstantinopoulos, P. A., Spentzos, D., & Cannistra, S. A. (2008). Gene-expression profiling in epithelial ovarian cancer. Nature Clinical Practice Oncology, 5(10), 577–587. doi:10.1038/ncponc1178.
28. Zorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V., Awtrey, C. S., Gardner, G. J., et al. (2005). Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clinical Cancer Research, 11(18), 6422–6430. doi:10.1158/1078-0432.ccr-05-0508.
29. Bonome, T., Lee, J. Y., Park, D. C., Radonovich, M., Pise-Masison, C., Brady, J., et al. (2005). Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Research, 65(22), 10602–10612. doi:10.1158/0008-5472.can-05-2240.
30. Morita, A., Miyagi, E., Yasumitsu, H., Kawasaki, H., Hirano, H., & Hirahara, F. (2006). Proteomic search for potential diagnostic markers and therapeutic targets for ovarian clear cell adenocarcinoma. Proteomics, 6(21), 5880–5890. doi:10.1002/pmic.200500708.
31. Longuespee, R., Gagnon, H., Boyon, C., Strupat, K., Dauly, C., Kerdraon, O., et al. (2013). Proteomic analyses of serous and endometrioid epithelial ovarian cancers—cases studies—molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics - Clinical Applications, 7(5–6), 337–354. doi:10.1002/prca.201200079.
32. Jia, L., Zhang, H., Qu, X., Deng, B., & Kong, B. (2012). Proteomic analysis reflects different histologic subtypes of epithelial ovarian cancer. Medical Hypotheses, 78(3), 407–409. doi:10.1016/j.mehy.2011.11.017.
33. Wiegand, K. C., Hennessy, B. T., Leung, S., Wang, Y., Ju, Z., McGahren, M., et al. (2014). A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer, 14, 120. doi:10.1186/1471-2407-14-120.
34. An, H. J., Kim, D. S., Park, Y. K., Kim, S. K., Choi, Y. P., Kang, S., et al. (2006). Comparative proteomics of ovarian epithelial tumors. Journal of Proteome Research, 5(5), 1082–1090. doi:10.1021/pr050461p.
35. Sereni, M. I., Baldelli, E., Gambara, G., Zanotti, L., Bandiera, E., Bignotti, E., et al. (2014). Functional characterization of epithelial ovarian cancer histotypes by drug target-based protein signaling activation mapping: implications for personalized cancer therapy. Proteomics. doi:10.1002/pmic.201400214.
36. Toyama, A., Suzuki, A., Shimada, T., Aoki, C., Aoki, Y., Umino, Y., et al. (2012). Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers. Cancer Science, 103(4), 747–755. doi:10.1111/j.1349-7006.2012.02224.x.
37. Zhu, Y., Wu, R., Sangha, N., Yoo, C., Cho, K. R., Shedden, K. A., et al. (2006). Classifications of ovarian cancer tissues by proteomic patterns. Proteomics, 6(21), 5846–5856. doi:10.1002/pmic.200600165.
38. Tian, Y., Yao, Z., Roden, R. B., & Zhang, H. (2011). Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. Proteomics, 11(24), 4677–4687. doi:10.1002/pmic.201000811.
39. Mann, M., & Jensen, O. N. (2003). Proteomic analysis of post-translational modifications. Nature Biotechnology, 21(3), 255–261. doi:10.1038/nbt0303-255.
40. Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S., & Brunak, S. (2004). Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics, 4(6), 1633–1649. doi:10.1002/pmic.200300771.
41. Abbott, K. L., Lim, J. M., Wells, L., Benigno, B. B., McDonald, J. F., & Pierce, M. (2010). Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. Proteomics, 10(3), 470–481. doi:10.1002/pmic.200900537.
42. Shetty, V., Hafner, J., Shah, P., Nickens, Z., & Philip, R. (2012). Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics. Clinical Proteomics, 9(1), 10. doi:10.1186/1559-0275-9-10.
43. Kuzmanov, U., Musrap, N., Kosanam, H., Smith, C. R., Batruch, I., Dimitromanolakis, A., et al. (2013). Glycoproteomic identification of potential glycoprotein biomarkers in ovarian cancer proximal fluids. Clinical Chemistry and Laboratory Medicine, 51(7), 1467–1476. doi:10.1515/cclm-2012-0642.
44. Fila, J., & Honys, D. (2012). Enrichment techniques employed in phosphoproteomics. Amino Acids, 43(3), 1025–1047. doi:10.1007/s00726-011-1111-z.
45. Longuespee, R., Boyon, C., Desmons, A., Vinatier, D., Leblanc, E., Farre, I., et al. (2012). Ovarian cancer molecular pathology. Cancer Metastasis Reviews, 31(3–4), 713–732. doi:10.1007/s10555-012-9383-7.
46. Cohen, J. G., White, M., Cruz, A., & Farias-Eisner, R. (2014). In 2014, can we do better than CA125 in the early detection of ovarian cancer? World Journal of Biological Chemistry, 5(3), 286–300. doi:10.4331/wjbc.v5.i3.286.
47. Yin, B. W., & Lloyd, K. O. (2001). Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. Journal of Biological Chemistry, 276(29), 27371–27375. doi:10.1074/jbc.M103554200.
48. Bast, R. C., Jr., Urban, N., Shridhar, V., Smith, D., Zhang, Z., Skates, S., et al. (2002). Early detection of ovarian cancer: promise and reality. Cancer Treatment and Research, 107, 61–97.
49. Fleming, N. D., Cass, I., Walsh, C. S., Karlan, B. Y., & Li, A. J. (2011). CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecologic Oncology, 121(2), 249–252. doi:10.1016/j.ygyno.2011.01.014.
50. Bast, R. C., Jr., Badgwell, D., Lu, Z., Marquez, R., Rosen, D., Liu, J., et al. (2005). New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 15(Suppl 3), 274–281. doi:10.1111/j.1525-1438.2005.00441.x.
51. Drapkin, R., von Horsten, H. H., Lin, Y., Mok, S. C., Crum, C. P., Welch, W. R., et al. (2005). Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research, 65(6), 2162–2169. doi:10.1158/0008-5472.can-04-3924.
52. Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, J. A., Schummer, M., McIntosh, M., et al. (2003). The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research, 63(13), 3695–3700.
53. Moore, R. G., Miller, M. C., Steinhoff, M. M., Skates, S. J., Lu, K. H., Lambert-Messerlian, G., et al. (2012). Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology, 206(4), 351 e351–358. doi:10.1016/j.ajog.2011.12.029.
54. Montagnana, M., Danese, E., Giudici, S., Franchi, M., Guidi, G. C., Plebani, M., et al. (2011). HE4 in ovarian cancer: from discovery to clinical application. Advances in Clinical Chemistry, 55, 1–20.
55. Moore, R. G., Miller, M. C., Disilvestro, P., Landrum, L. M., Gajewski, W., Ball, J. J., et al. (2011). Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics and Gynecology, 118(2 Pt 1), 280–288. doi:10.1097/AOG.0b013e318224fce2.
56. Nolen, B., Velikokhatnaya, L., Marrangoni, A., De Geest, K., Lomakin, A., Bast, R. C., Jr., et al. (2010). Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology, 117(3), 440–445. doi:10.1016/j.ygyno.2010.02.005.
57. Escudero, J. M., Auge, J. M., Filella, X., Torne, A., Pahisa, J., & Molina, R. (2011). Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clinical Chemistry, 57(11), 1534–1544. doi:10.1373/clinchem.2010.157073.
58. Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., et al. (2011). HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer, 104(5), 863–870. doi:10.1038/sj.bjc.6606092.
59. Montagnana, M., Danese, E., Ruzzenente, O., Bresciani, V., Nuzzo, T., Gelati, M., et al. (2011). The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clinical Chemistry and Laboratory Medicine, 49(3), 521–525. doi:10.1515/cclm.2011.075.
60. Moore, R. G., McMeekin, D. S., Brown, A. K., DiSilvestro, P., Miller, M. C., Allard, W. J., et al. (2009). A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology, 112(1), 40–46. doi:10.1016/j.ygyno.2008.08.031.
61. Rodland, K. D., & Maihle, N. J. (2010). Searching for a system: the quest for ovarian cancer biomarkers. Cancer Biomarkers, 8(4–5), 223–230. doi:10.3233/cbm-2011-0216.
62. Zhang, B., Cai, F. F., & Zhong, X. Y. (2011). An overview of biomarkers for the ovarian cancer diagnosis. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 158(2), 119–123. doi:10.1016/j.ejogrb.2011.04.023.
63. Zhang, Z., Bast, R. C., Jr., Yu, Y., Li, J., Sokoll, L. J., Rai, A. J., et al. (2004). Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Research, 64(16), 5882–5890. doi:10.1158/0008-5472.can-04-0746.
64. Ueland, F. R., Desimone, C. P., Seamon, L. G., Miller, R. A., Goodrich, S., Podzielinski, I., et al. (2011). Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics and Gynecology, 117(6), 1289–1297. doi:10.1097/AOG.0b013e31821b5118.
65. Vernooij, F., Heintz, P., Witteveen, E., & van der Graaf, Y. (2007). The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecologic Oncology, 105(3), 801–812. doi:10.1016/j.ygyno.2007.02.030.
66. Wegdam, W., Argmann, C. A., Kramer, G., Vissers, J. P., Buist, M. R., Kenter, G. G., et al. (2014). Label-free LC-MSe in tissue and Serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors. PLoS One, 9(9), e108046. doi:10.1371/journal.pone.0108046.
67. Kozak, K. R., Su, F., Whitelegge, J. P., Faull, K., Reddy, S., & Farias-Eisner, R. (2005). Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 5(17), 4589–4596. doi:10.1002/pmic.200500093.
68. Ahmed, N., Oliva, K. T., Barker, G., Hoffmann, P., Reeve, S., Smith, I. A., et al. (2005). Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics, 5(17), 4625–4636. doi:10.1002/pmic.200401321.
69. Pan, S., Chen, R., Aebersold, R., & Brentnall, T. A. (2011). Mass spectrometry based glycoproteomics—from a proteomics perspective. Molecular and Cellular Proteomics, 10(1), R110 003251. doi:10.1074/mcp.R110.003251.
70. Faca, V. M., Ventura, A. P., Fitzgibbon, M. P., Pereira-Faca, S. R., Pitteri, S. J., Green, A. E., et al. (2008). Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One, 3(6), e2425. doi:10.1371/journal.pone.0002425.
71. Gunawardana, C. G., Kuk, C., Smith, C. R., Batruch, I., Soosaipillai, A., & Diamandis, E. P. (2009). Comprehensive analysis of conditioned media from ovarian cancer cell lines identifies novel candidate markers of epithelial ovarian cancer. Journal of Proteome Research, 8(10), 4705–4713. doi:10.1021/pr900411g.
72. Zhang, Y., Xu, B., Liu, Y., Yao, H., Lu, N., Li, B., et al. (2012). The ovarian cancer-derived secretory/releasing proteome: a repertoire of tumor markers. Proteomics, 12(11), 1883–1891. doi:10.1002/pmic.201100654.
73. Gortzak-Uzan, L., Ignatchenko, A., Evangelou, A. I., Agochiya, M., Brown, K. A., St Onge, P., et al. (2008). A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. Journal of Proteome Research, 7(1), 339–351. doi:10.1021/pr0703223.
74. Kuk, C., Kulasingam, V., Gunawardana, C. G., Smith, C. R., Batruch, I., & Diamandis, E. P. (2009). Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Molecular and Cellular Proteomics, 8(4), 661–669. doi:10.1074/mcp. M800313-MCP200.
75. Kristjansdottir, B., Levan, K., Partheen, K., Carlsohn, E., & Sundfeldt, K. (2013). Potential tumor biomarkers identified in ovarian cyst fluid by quantitative proteomic analysis, iTRAQ. Clinical Proteomics, 10(1), 4. doi:10.1186/1559-0275-10-4.
76. Davidson, B., Espina, V., Steinberg, S. M., Florenes, V. A., Liotta, L. A., Kristensen, G. B., et al. (2006). Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. Clinical Cancer Research, 12(3 Pt 1), 791–799. doi:10.1158/1078-0432.ccr-05-2516.
77. Petri, A. L., Simonsen, A. H., Yip, T. T., Hogdall, E., Fung, E. T., Lundvall, L., et al. (2009). Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology. Acta Obstetricia et Gynecologica Scandinavica, 88(1), 18–26. doi:10.1080/00016340802443830.
78. Moyer, V. A. (2012). Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Annals of Internal Medicine, 157(12), 900–904. doi:10.7326/0003-4819-157-11-201212040-00539.
79. American College of, O., & Gynecologists Committee on Gynecologic, P. (2011). Committee Opinion No. 477: the role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer. Obstetrics and Gynecology, 117(3), 742–746. doi:10.1097/AOG.0b013e31821477db.
80. Buys, S. S., Partridge, E., Black, A., Johnson, C. C., Lamerato, L., Isaacs, C., et al. (2011). Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA, 305(22), 2295–2303. doi:10.1001/jama.2011.766.
81. Kobayashi, H., Yamada, Y., Sado, T., Sakata, M., Yoshida, S., Kawaguchi, R., et al. (2008). A randomized study of screening for ovarian cancer: a multicenter study in Japan. International Journal of Gynecological Cancer, 18(3), 414–420. doi:10.1111/j.1525-1438.2007.01035.x.
82. Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, 10(4), 327–340. doi:10.1016/s1470-2045(09)70026-9.
83. Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., et al. (2003). Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 21(17), 3194–3200. doi:10.1200/jco.2003.02.153.
84. Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012). Therapeutic strategies in epithelial ovarian cancer. Journal of Experimental & Clinical Cancer Research, 31, 14. doi:10.1186/1756-9966-31-14.
85. Fountain, J., Trimble, E., & Birrer, M. J. (2006). Summary and discussion of session recommendations. Gynecologic Oncology, 103(2 Suppl 1), S23–S25. doi:10.1016/j.ygyno.2006.08.022.
86. Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., et al. (2005). Gene expression profiles predict early relapse in ovarian cancer after platinum–paclitaxel chemotherapy. Clinical Cancer Research, 11(6), 2149–2155. doi:10.1158/1078-0432.ccr-04-1673.
87. Berchuck, A., Iversen, E. S., Lancaster, J. M., Dressman, H. K., West, M., Nevins, J. R., et al. (2004). Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. American Journal of Obstetrics and Gynecology, 190(4), 910–925. doi:10.1016/j.ajog.2004.02.005.
88. Spentzos, D., Levine, D. A., Ramoni, M. F., Joseph, M., Gu, X., Boyd, J., et al. (2004). Gene expression signature with independent prognostic significance in epithelial ovarian cancer. Journal of Clinical Oncology, 22(23), 4700–4710. doi:10.1200/jco.2004.04.070.
89. Potti, A., Dressman, H. K., Bild, A., Riedel, R. F., Chan, G., Sayer, R., et al. (2006). Genomic signatures to guide the use of chemotherapeutics. Nature Medicine, 12(11), 1294–1300. doi:10.1038/nm1491.
90. Agarwal, R., & Kaye, S. B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nature Reviews Cancer, 3(7), 502–516. doi:10.1038/nrc1123.
91. Li, S.-L., Ye, F., Cai, W.-J., Hu, H.-D., Hu, P., Ren, H., et al. (2010). Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. Journal of Cellular Biochemistry, 109(4), 625–633. doi:10.1002/jcb.22413.
92. Yan, X. D., Pan, L. Y., Yuan, Y., Lang, J. H., & Mao, N. (2007). Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. Journal of Proteome Research, 6(2), 772–780. doi:10.1021/pr060402r.
93. Di Michele, M., Marcone, S., Cicchillitti, L., Della Corte, A., Ferlini, C., Scambia, G., et al. (2010). Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. Journal of Proteomics, 73(5), 879–898. doi:10.1016/j.jprot.2009.11.012.
94. Dai, Z., Yin, J., He, H., Li, W., Hou, C., Qian, X., et al. (2010). Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Proteomics, 10(21), 3789–3799. doi:10.1002/pmic.200900685.
95. Lee, D. H., Chung, K., Song, J. A., Kim, T. H., Kang, H., Huh, J. H., et al. (2010). Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. Journal of Proteome Research, 9(11), 5668–5676. doi:10.1021/pr100478u.
96. Chappell, N. P., Teng, P. N., Hood, B. L., Wang, G., Darcy, K. M., Hamilton, C. A., et al. (2012). Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. Journal of Proteome Research, 11(9), 4605–4614. doi:10.1021/pr300403d.
97. Chen, X., Wei, S., Ma, Y., Lu, J., Niu, G., Xue, Y., et al. (2014). Quantitative proteomics analysis identifies mitochondria as therapeutic targets of multidrug-resistance in ovarian cancer. Theranostics, 4(12), 1164–1175. doi:10.7150/thno.8502.
98. Cicchillitti, L., Di Michele, M., Urbani, A., Ferlini, C., Donat, M. B., Scambia, G., et al. (2009). Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. Journal of Proteome Research, 8(4), 1902–1912.
99. Le Moguen, K., Lincet, H., Marcelo, P., Lemoisson, E., Heutte, N., Duval, M., et al. (2007). A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Proteomics, 7(22), 4090–4101. doi:10.1002/pmic.200700231.
100. Yang, J. Y., Yoshihara, K., Tanaka, K., Hatae, M., Masuzaki, H., Itamochi, H., et al. (2013). Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation, 123(9), 3740–3750. doi:10.1172/jci68509.
101. Lee, J. M., Hays, J. L., Annunziata, C. M., Noonan, A. M., Minasian, L., Zujewski, J. A., et al. (2014). Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. Journal of the National Cancer Institute, 106(6), dju089. doi:10.1093/jnci/dju089.
102. Carey, M. S., Agarwal, R., Gilks, B., Swenerton, K., Kalloger, S., Santos, J., et al. (2010). Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF–beta pathway signaling indicates response to primary chemotherapy. Clinical Cancer Research, 16(10), 2852–2860. doi:10.1158/1078-0432.ccr-09-2502.
103. Picotti, P., Lam, H., Campbell, D., Deutsch, E. W., Mirzaei, H., Ranish, J., et al. (2008). A database of mass spectrometric assays for the yeast proteome. Nature Methods, 5(11), 913–914. doi:10.1038/nmeth1108-913.
104. Chen, Y., Gruidl, M., Remily-Wood, E., Liu, R. Z., Eschrich, S., Lloyd, M., et al. (2010). Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. Journal of Proteome Research, 9(8), 4215–4227. doi:10.1021/pr1005197.
105. Schrader, M., Schulz-Knappe, P., & Fricker, L. D. (2014). Historical perspective of peptidomics. EuPA Open Proteomics, 3, 171–182. doi:10.1016/j.euprot.2014.02.014.
106. Villanueva, J., Shaffer, D. R., Philip, J., Chaparro, C. A., Erdjument-Bromage, H., Olshen, A. B., et al. (2006). Differential exoprotease activities confer tumor-specific serum peptidome patterns. Journal of Clinical Investigation, 116(1), 271–284. doi:10.1172/jci26022.
107. Lopez, M. F., Mikulskis, A., Kuzdzal, S., Golenko, E., Petricoin, E. F., 3rd, Liotta, L. A., et al. (2007). A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clinical Chemistry, 53(6), 1067–1074. doi:10.1373/clinchem.2006.080721.
108. Fredolini, C., Meani, F., Luchini, A., Zhou, W., Russo, P., Ross, M., et al. (2010). Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. The AAPS Journal, 12(4), 504–518. doi:10.1208/s12248-010-9211-3.
109. Xu, Z., Wu, C., Xie, F., Slysz, G. W., Tolic, N., Monroe, M. E., et al. (2014). Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. Journal of Proteome Research. doi:10.1021/pr500840w.
110. Pan, B. T., & Johnstone, R. M. (1983). Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell, 33(3), 967–978.
111. Ciechanover, A., Schwartz, A. L., Dautry-Varsat, A., & Lodish, H. F. (1983). Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. Journal of Biological Chemistry, 258(16), 9681–9689.
112. E. L. A, S., Mager, I., Breakefield, X. O., & Wood, M. J. (2013). Extracellular vesicles: biology and emerging therapeutic opportunities. Nature Reviews Drug Discovery, 12(5), 347–357. doi:10.1038/nrd3978.
113. Azmi, A. S., Bao, B., & Sarkar, F. H. (2013). Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Reviews, 32(3–4), 623–642. doi:10.1007/s10555-013-9441-9.
114. Chairoungdua, A., Smith, D. L., Pochard, P., Hull, M., & Caplan, M. J. (2010). Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. Journal of Cell Biology, 190(6), 1079–1091. doi:10.1083/jcb.201002049.
115. Cho, J. A., Park, H., Lim, E. H., & Lee, K. W. (2012). Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. International Journal of Oncology, 40(1), 130–138. doi:10.3892/ijo.2011.1193.
116. Shedden, K., Xie, X. T., Chandaroy, P., Chang, Y. T., & Rosania, G. R. (2003). Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Research, 63(15), 4331–4337.
117. Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., et al. (2005). Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Molecular Cancer Therapeutics, 4(10), 1595–1604. doi:10.1158/1535-7163.mct-05-0102.
118. Beach, A., Zhang, H. G., Ratajczak, M. Z., & Kakar, S. S. (2014). Exosomes: an overview of biogenesis, composition and role in ovarian cancer. Journal of Ovarian Research, 7(1), 14. doi:10.1186/1757-2215-7-14.
119. Sinha, A., Ignatchenko, V., Ignatchenko, A., Mejia-Guerrero, S., & Kislinger, T. (2014). In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome. Biochemical and Biophysical Research Communications, 445(4), 694–701. doi:10.1016/j.bbrc.2013.12.070.
120. Pisitkun, T., Gandolfo, M. T., Das, S., Knepper, M. A., & Bagnasco, S. M. (2012). Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation. Proteomics - Clinical Applications, 6(5–6), 268–278. doi:10.1002/prca.201100108.
121. Kalra, H., Adda, C. G., Liem, M., Ang, C. S., Mechler, A., Simpson, R. J., et al. (2013). Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics, 13(22), 3354–3364. doi:10.1002/pmic.201300282.
122. Zubiri, I., Vivanco, F., & Alvarez-Llamas, G. (2013). Proteomic analysis of urinary exosomes in cardiovascular and associated kidney diseases by two-dimensional electrophoresis and LC-MS/MS. Methods in Molecular Biology, 1000, 209–220. doi:10.1007/978-1-62703-405-0_16.
123. Street, J. M., Barran, P. E., Mackay, C. L., Weidt, S., Balmforth, C., Walsh, T. S., et al. (2012). Identification and proteomic profiling of exosomes in human cerebrospinal fluid. Journal of Translational Medicine, 10, 5. doi:10.1186/1479-5876-10-5.
124. Xiao, H., & Wong, D. T. (2012). Proteomic analysis of microvesicles in human saliva by gel electrophoresis with liquid chromatography-mass spectrometry. Analitica Chimica Acta, 723, 61–67. doi:10.1016/j.aca.2012.02.018.
125. Admyre, C., Johansson, S. M., Qazi, K. R., Filen, J. J., Lahesmaa, R., Norman, M., et al. (2007). Exosomes with immune modulatory features are present in human breast milk. Journal of Immunology, 179(3), 1969–1978.
126. Liang, B., Peng, P., Chen, S., Li, L., Zhang, M., Cao, D., et al. (2013). Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of Proteomics, 80, 171–182. doi:10.1016/j.jprot.2012.12.029.
127. Hortin, G. L., & Sviridov, D. (2010). The dynamic range problem in the analysis of the plasma proteome. Journal of Proteomics, 73(3), 629–636. doi:10.1016/j.jprot.2009.07.001.
128. Fernando, S. A., & Wilson, G. S. (1992). Studies of the ‘hook’ effect in the one-step sandwich immunoassay. Journal of Immunological Methods, 151(1–2), 47–66.
129. Ioannidis, J. P. (2013). Biomarker failures. Clinical Chemistry, 59(1), 202–204. doi:10.1373/clinchem.2012.185801.
130. Gagne, J. P., Ethier, C., Gagne, P., Mercier, G., Bonicalzi, M. E., Mes-Masson, A. M., et al. (2007). Comparative proteome analysis of human epithelial ovarian cancer. Proteome Science, 5, 16. doi:10.1186/1477-5956-5-16.
131. Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013). Evaluating cell lines as tumour models by comparison of genomic profiles. Nature Communications, 4, 2126. doi:10.1038/ncomms3126.
132. Wei, B. R., Hoover, S. B., Ross, M. M., Zhou, W., Meani, F., Edwards, J. B., et al. (2009). Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One, 4(10), e7670. doi:10.1371/journal.pone.0007670.
133. He, Y., Wu, X., Liu, X., Yan, G., & Xu, C. (2010). LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker. Journal of Proteome Research, 9(12), 6180–6190. doi:10.1021/pr100822v.
134. Pitteri, S. J., JeBailey, L., Faca, V. M., Thorpe, J. D., Silva, M. A., Ireton, R. C., et al. (2009). Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery. PLoS One, 4(11), e7916. doi:10.1371/journal.pone.0007916.
135. Tang, H. Y., Beer, L. A., Chang-Wong, T., Hammond, R., Gimotty, P., Coukos, G., et al. (2012). A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. Journal of Proteome Research, 11(2), 678–691. doi:10.1021/pr200603h.
136. Parker, W. H., Broder, M. S., Chang, E., Feskanich, D., Farquhar, C., Liu, Z., et al. (2009). Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstetrics and Gynecology, 113(5), 1027–1037. doi:10.1097/AOG.0b013e3181a11c64.
137. Harsha, H. C., & Pandey, A. (2010). Phosphoproteomics in cancer. Molecular Oncology, 4(6), 482–495. doi:10.1016/j.molonc.2010.09.004.
138. Naumann, R. W., & Coleman, R. L. (2011). Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71(11), 1397–1412. doi:10.2165/11591720-000000000-00000.
139. Yap, T. A., Carden, C. P., & Kaye, S. B. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer, 9(3), 167–181. doi:10.1038/nrc2583.
140. Lee, J. M., Ledermann, J. A., & Kohn, E. C. (2014). PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Annals of Oncology, 25(1), 32–40. doi:10.1093/annonc/mdt384.
141. Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434(7035), 917–921. doi:10.1038/nature03445.
142. Dunn, L., & Demichele, A. (2009). Genomic predictors of outcome and treatment response in breast cancer. Molecular Diagnosis & Therapy, 13(2), 73–90. doi:10.2165/01250444-200913020-00002.
143. Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., et al. (2014). Assessing the clinical utility of cancer genomic and proteomic data across tumor types. [Computational Biology]. Nature Biotechnology, 32(7), 644–652. doi:10.1038/nbt.2940.